JP2024520522A5 - - Google Patents

Info

Publication number
JP2024520522A5
JP2024520522A5 JP2023573300A JP2023573300A JP2024520522A5 JP 2024520522 A5 JP2024520522 A5 JP 2024520522A5 JP 2023573300 A JP2023573300 A JP 2023573300A JP 2023573300 A JP2023573300 A JP 2023573300A JP 2024520522 A5 JP2024520522 A5 JP 2024520522A5
Authority
JP
Japan
Prior art keywords
rnai agent
agent according
nucleotide
sense strand
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023573300A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520522A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/030969 external-priority patent/WO2022251394A1/en
Publication of JP2024520522A publication Critical patent/JP2024520522A/ja
Publication of JP2024520522A5 publication Critical patent/JP2024520522A5/ja
Pending legal-status Critical Current

Links

JP2023573300A 2021-05-28 2022-05-25 ムチン５ＡＣ（ＭＵＣ５ＡＣ）の発現を阻害するためのＲＮＡｉ剤、その組成物、及び使用方法 Pending JP2024520522A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163194370P 2021-05-28 2021-05-28
US63/194,370 2021-05-28
PCT/US2022/030969 WO2022251394A1 (en) 2021-05-28 2022-05-25 Rnai agents for inhibiting expression of mucin 5ac (muc5ac), compositions thereof, and methods of use

Publications (2)

Publication Number Publication Date
JP2024520522A JP2024520522A (ja) 2024-05-24
JP2024520522A5 true JP2024520522A5 (enExample) 2025-06-02

Family

ID=84229166

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023573300A Pending JP2024520522A (ja) 2021-05-28 2022-05-25 ムチン５ＡＣ（ＭＵＣ５ＡＣ）の発現を阻害するためのＲＮＡｉ剤、その組成物、及び使用方法

Country Status (15)

Country Link
US (1) US12365897B2 (enExample)
EP (1) EP4352229A4 (enExample)
JP (1) JP2024520522A (enExample)
KR (1) KR20240014067A (enExample)
CN (1) CN117858949A (enExample)
AU (1) AU2022280863A1 (enExample)
BR (1) BR112023024615A2 (enExample)
CA (1) CA3218815A1 (enExample)
CL (1) CL2023003505A1 (enExample)
CO (1) CO2023016058A2 (enExample)
IL (1) IL308883A (enExample)
MX (1) MX2023014026A (enExample)
PE (1) PE20250265A1 (enExample)
TW (1) TW202313068A (enExample)
WO (1) WO2022251394A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024158905A1 (en) * 2023-01-24 2024-08-02 Ohio State Innovation Foundation Muc5ac in pancreatic ductal adenocarcinoma
WO2025128462A1 (en) * 2023-12-12 2025-06-19 Eli Lilly And Company Novel therapeutic delivery moieties and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
DE60040274D1 (de) 1999-03-10 2008-10-30 Phogen Ltd Verabreichung von nukleinsäuren und proteinen an zellen
AU2003295600A1 (en) * 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
US7820380B2 (en) 2004-05-07 2010-10-26 Celera Corporation Genetic polymorphisms associated with liver fibrosis
CN101500548A (zh) 2006-08-18 2009-08-05 弗·哈夫曼-拉罗切有限公司 用于体内递送多核苷酸的多缀合物
WO2010067882A1 (ja) * 2008-12-12 2010-06-17 株式会社クレハ 癌及び喘息治療のための医薬組成物
SI2539451T1 (sl) 2010-02-24 2016-04-29 Arrowhead Research Corporation Sestavki za ciljano dostavo sirna
ES2719624T3 (es) 2010-09-23 2019-07-11 Prec Biologics Inc Peptidomiméticos de cáncer de colon y de páncreas
US9920317B2 (en) * 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
WO2013032829A1 (en) 2011-08-26 2013-03-07 Arrowhead Research Corporation Poly(vinyl ester) polymers for in vivo nucleic acid delivery
CA2842041A1 (en) 2012-04-18 2013-10-24 Arrowhead Research Corporation Poly(acrylate) polymers for in vivo nucleic acid delivery
US9452228B2 (en) * 2013-04-01 2016-09-27 Immunomedics, Inc. Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2)
CA2948013A1 (en) 2014-06-30 2016-01-07 Immunomedics, Inc. Antibodies reactive with an epitope located in the n-terminal region of muc5ac comprising cysteine-rich subdomain 2 (cys2)
MX2018015109A (es) 2016-06-06 2019-04-22 Arrowhead Pharmaceuticals Inc Nucleotidos modificados con 5'-ciclo-fosfonato.
JOP20190015A1 (ar) * 2016-08-04 2019-02-04 Arrowhead Pharmaceuticals Inc عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
SI3535397T1 (sl) 2016-11-01 2022-04-29 Arrowhead Pharmaceuticals, Inc. Ligandi alfa-V beta-6 integrina in njihove uporabe
WO2019089765A1 (en) * 2017-11-01 2019-05-09 Arrowhead Pharmcaceuticals, Inc. Integrin ligands and uses thereof
JP7420727B2 (ja) 2018-02-17 2024-01-23 アローヘッド ファーマシューティカルズ インコーポレイテッド トリアルキン結合剤及び使用方法
US11040056B2 (en) * 2018-05-11 2021-06-22 The University Of North Carolina At Chapel Hill Benzimidazoles that enhance the activity of oligonucleotides

Similar Documents

Publication Publication Date Title
JP2020533334A5 (enExample)
JP6799058B2 (ja) アレル選択的な遺伝子編集およびその使用
JP2024516096A5 (enExample)
JP2025185070A5 (enExample)
TWI835719B (zh) 經修飾之嚮導rna
CN110846316B (zh) 在基因沉默中具有降低的脱靶效应的una寡聚物
JP2018529732A5 (enExample)
JP2024520522A5 (enExample)
JP2022502055A5 (enExample)
JP2023536974A5 (enExample)
JP2020526192A5 (enExample)
JP2024539193A5 (enExample)
JP2023519246A5 (enExample)
TW201726918A (zh) 抑制lpa之基因表現之組合物及方法
JP2024541962A5 (enExample)
JP2013535212A5 (enExample)
JP2019513372A5 (enExample)
JP2026069791A (ja) Ｈｂｖの処置のためのｈｂｖを標的とする治療用オリゴヌクレオチドとｔｌｒ７アゴニストとの医薬組合せ
JP2021531804A5 (enExample)
TW202221122A (zh) Ｂ型肝炎患者之寡核苷酸治療
JP2022518384A5 (enExample)
JP2025500860A5 (enExample)
JP2017510583A (ja) 遺伝子サイレンシング用トランスサイレチン対立遺伝子選択的ｕｎａオリゴマー
JP2025527583A (ja) 脂質ナノ粒子の組成物
JP2011515357A5 (enExample)